Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Acquired by SBI Securities Co. Ltd.

SBI Securities Co. Ltd. raised its stake in Seres Therapeutics, Inc. (NASDAQ:MCRB - Free Report) by 221.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,664 shares of the biotechnology company's stock after purchasing an additional 48,013 shares during the period. SBI Securities Co. Ltd. owned 0.80% of Seres Therapeutics worth $49,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in MCRB. Charles Schwab Investment Management Inc. grew its position in shares of Seres Therapeutics by 15.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock worth $720,000 after acquiring an additional 117,107 shares during the last quarter. Avantax Advisory Services Inc. grew its position in shares of Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 28,500 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Seres Therapeutics by 8.8% during the fourth quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company's stock worth $1,256,000 after purchasing an additional 121,793 shares during the period. Northern Trust Corp lifted its holdings in shares of Seres Therapeutics by 20.4% during the fourth quarter. Northern Trust Corp now owns 262,683 shares of the biotechnology company's stock worth $218,000 after purchasing an additional 44,461 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after purchasing an additional 37,866 shares during the period. 59.34% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Stock Performance

Seres Therapeutics stock traded up $0.70 during midday trading on Wednesday, reaching $13.09. The company's stock had a trading volume of 168,975 shares, compared to its average volume of 129,545. Seres Therapeutics, Inc. has a fifty-two week low of $6.53 and a fifty-two week high of $29.40. The stock's 50 day simple moving average is $9.49 and its 200 day simple moving average is $12.13. The firm has a market capitalization of $114.28 million, a PE ratio of -2.85 and a beta of 2.75.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). Equities analysts predict that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on MCRB shares. Wall Street Zen raised Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 9th. Chardan Capital reaffirmed a "neutral" rating and set a $6.00 price target (up from $1.25) on shares of Seres Therapeutics in a report on Thursday, May 8th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Seres Therapeutics presently has a consensus rating of "Hold" and an average price target of $73.67.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.